Relevant adverse events presented by patients and by highest intensity
| . | Grade 1-2 . | Grade 3 . | Grade 4 . | Grade 5 . |
|---|---|---|---|---|
| Hematologic toxicity | ||||
| Neutropenia | 5 (6) | 15 (19) | 55 (71) | 0 (0) |
| Anemia | 27 (34) | 26 (33) | 3 (3) | 0 (0) |
| Thrombocytopenia | 12 (15) | 12 (15) | 24 (31) | 0 (0) |
| Febrile neutropenia | 0 (0) | 9 (11) | 4 (5) | 0 (0) |
| Infection | ||||
| Sepsis | 1 (1) | 5 (6) | 6 (8) | 4 (5)* |
| Pneumonia | 1 (1) | 5 (5) | 1 (1) | 0 (0) |
| Upper respiratory tract infection | 12 (15) | 0 (0) | 0 (0) | 0 (0) |
| Digestive tract infection | 0 (0) | 2 (3) | 0 (0) | 0 (0) |
| Urinary tract infection | 4 (5) | 2 (3) | 0 (0) | 0 (0) |
| Other | 9 (12) | 2 (3) | 1 (1) | 0 (0) |
| Nonhematologic adverse events | ||||
| Fatigue | 15 (19) | 4 (5) | 0 (0) | 0 (0) |
| Nausea/vomiting | 18 (23) | 4 (5) | 0 (0) | 0 (0) |
| Peripheral neuropathy | 12 (15) | 2 (3) | 0 (0) | 0 (0) |
| Rash | 7 (9) | 2 (3) | 0 (0) | 0 (0) |
| Thrombosis | 7 (9) | 1 (1) | 0 (0) | 0 (0) |
| . | Grade 1-2 . | Grade 3 . | Grade 4 . | Grade 5 . |
|---|---|---|---|---|
| Hematologic toxicity | ||||
| Neutropenia | 5 (6) | 15 (19) | 55 (71) | 0 (0) |
| Anemia | 27 (34) | 26 (33) | 3 (3) | 0 (0) |
| Thrombocytopenia | 12 (15) | 12 (15) | 24 (31) | 0 (0) |
| Febrile neutropenia | 0 (0) | 9 (11) | 4 (5) | 0 (0) |
| Infection | ||||
| Sepsis | 1 (1) | 5 (6) | 6 (8) | 4 (5)* |
| Pneumonia | 1 (1) | 5 (5) | 1 (1) | 0 (0) |
| Upper respiratory tract infection | 12 (15) | 0 (0) | 0 (0) | 0 (0) |
| Digestive tract infection | 0 (0) | 2 (3) | 0 (0) | 0 (0) |
| Urinary tract infection | 4 (5) | 2 (3) | 0 (0) | 0 (0) |
| Other | 9 (12) | 2 (3) | 1 (1) | 0 (0) |
| Nonhematologic adverse events | ||||
| Fatigue | 15 (19) | 4 (5) | 0 (0) | 0 (0) |
| Nausea/vomiting | 18 (23) | 4 (5) | 0 (0) | 0 (0) |
| Peripheral neuropathy | 12 (15) | 2 (3) | 0 (0) | 0 (0) |
| Rash | 7 (9) | 2 (3) | 0 (0) | 0 (0) |
| Thrombosis | 7 (9) | 1 (1) | 0 (0) | 0 (0) |
Data are n (%). Hematologic adverse events, infection, and events occurring in more than 15% of the 78 patients.
*Patient died of septic shock, related to treatment, and had progressive lymphoma.